Baricitinib (brand name Olumiant) belongs to a new class of medicines called ‘targeted synthetic disease modifying antirheumatic drugs’ (tsD

Tofacitinib (brand name: Xeljanz) belongs to a class of medicines called non-biological disease modifying antirheumatic drugs (non-biologica